Lexaria Enterprise Value Multiple from 2010 to 2025

LEXXW Stock  USD 0.25  0  0.44%   
Lexaria Bioscience Enterprise Value Multiple yearly trend continues to be fairly stable with very little volatility. Enterprise Value Multiple is likely to outpace its year average in 2025. During the period from 2010 to 2025, Lexaria Bioscience Enterprise Value Multiple regression line of quarterly data had mean square error of  14,015 and geometric mean of  5.08. View All Fundamentals
 
Enterprise Value Multiple  
First Reported
2010-12-31
Previous Quarter
395.76913088
Current Value
415.56
Quarterly Volatility
139.65728919
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 129 K, Interest Expense of 125.2 K or Other Operating Expenses of 7.5 M, as well as many indicators such as Price To Sales Ratio of 140, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Latest Lexaria Bioscience's Enterprise Value Multiple Growth Pattern

Below is the plot of the Enterprise Value Multiple of Lexaria Bioscience Corp over the last few years. It is Lexaria Bioscience's Enterprise Value Multiple historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Multiple10 Years Trend
Slightly volatile
   Enterprise Value Multiple   
       Timeline  

Lexaria Enterprise Value Multiple Regression Statistics

Arithmetic Mean48.04
Geometric Mean5.08
Coefficient Of Variation290.72
Mean Deviation89.41
Median(2.91)
Standard Deviation139.66
Sample Variance19,504
Range423
R-Value0.57
Mean Square Error14,015
R-Squared0.33
Significance0.02
Slope16.83
Total Sum of Squares292,562

Lexaria Enterprise Value Multiple History

2025 415.56
2024 395.77
2023 -7.41
2022 -0.9
2021 -1.79
2020 -2.96
2019 -2.82

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Enterprise Value Multiple, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Multiple 395.77  415.56 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.